Product Description
Addpharma is developing AD-2081 as a treatment for Androgenetic Alopecia. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04825561)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Addpharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Korea